Clinical trial · Observational
Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma
NCT06761599CI-TRIAL-00084417active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| group 1 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- high-resolution computed tomography
- timeFrame
- 12 Months
- description
- An HRCT (high-resolution computed tomography) scan is a type of CT scan healthcare providers use to get detailed images of your lungs. Providers most commonly use it to diagnose and monitor interstitial lung diseases and conditions that affect your small airways and alveoli (air sacs).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with Hodgkin lymphoma (HL) receiving treatment. * Patients of all ages and both genders. * Patients with histologically confirmed HL, as per the WHO 2016 classification. * Patients who have undergone pulmonary function testing and assessment at specified time points during their treatment course. * Patients with complete medical records documenting treatment regimens, including chemotherapy and radiotherapy details. Exclusion Criteria: * Patients with a diagnosis of another malignancy. * Patients with incomplete medical records or missing data on treatment regimens and pulmonary function assessments. * Patients with a history of significant pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis, before HL diagnosis. * Patients who are unable to complete pulmonary function tests.
References
Publications (0)
Data not yet available
No reference posted for this study.